Coagulation Factor VII in Middle-aged Women with and without Coronary Heart Disease

Margita Eriksson-Berg; Angela Silveira; Kristina Orth-Gomér; Anders Hamsten; Karin Schenck-Gustafsson

doi:10.1055/s-0037-1615719

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 85(05): 787-792
DOI: 10.1055/s-0037-1615719

Review Article

Schattauer GmbH

Coagulation Factor VII in Middle-aged Women with and without Coronary Heart Disease

Margita Eriksson-Berg

¹Cardiology Unit and the Atherosclerosis Research Unit

,

Angela Silveira

²Atherosclerosis Research Unit, King Gustaf V Research Institute Department of Medicine, Karolinska Hospital

,

Kristina Orth-Gomér

³Department of Public Health Sciences, Division of Preventive Medicine, Karolinska Institutet, Stockholm, Sweden

,

Anders Hamsten

²Atherosclerosis Research Unit, King Gustaf V Research Institute Department of Medicine, Karolinska Hospital

,

Karin Schenck-Gustafsson

¹Cardiology Unit and the Atherosclerosis Research Unit

› Author Affiliations

Abstract

Summary

Epidemiological studies of coagulation factor VII as a risk factor for coronary heart disease (CHD), mainly conducted in men, have shown discrepant results. We examined the associations of coagulation factor VII antigen (VIIag) and activated factor VII (VIIa) with manifest CHD in a community-based case-control study of women aged ≤65 years. Mean plasma concentrations of VIIag and VIIa in patients and controls were 443 ± 108 and 418 ± 89 ng/L (p <0.01) and 5.26 ± 2.21 and 4.90 ± 1.65 ng/L (NS), respectively. The odds ratio (OR) for CHD for the highest versus the lowest quartile of VIIag was 1.75 (95% CI, 1.05 to 2.92). The adjusted OR was 0.76 (95% CI, 0.28-1.98) after controlling for other cardiovascular risk factors. The corresponding ORs for VIIa were non-significant. In conclusion, the plasma concentration of VIIa was not significantly increased in a large group of women with precocious CHD, and VIIag levels, although elevated, were not independently associated with manifest disease.

Keywords

Factor VII - lipoproteins - risk factors - myocardial infarction - coronary heart disease

Full Text

References

References
1 Hamsten A. The hemostatic system and coronary heart disease. Thromb Research 1993; 70: 1-38.
2 Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-8.
3 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
4 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
5 Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
6 Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-9. Erratum. Arterioscler Thromb 1994; 14: 1392.
7 Hoffman CJ, Miller RH, Lawson WE, Hultin MB. Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol 1989; 14: 941-6.
8 Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990; 85: 169-73.
9 Suzuki T, Yamauchi K, Matsushita T, Furumichi T, Furui H, Tsuzuki J, Saito H. Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clin Cardiol 1991; 14: 731-6.
10 Redondo M, Watzke HH, Stucki B, Sulzer I, Demarmelis Biasiutti F, Binder BR, Furlan M, Lämmle B, Wuillemin WA. Coagulation factor II, V, VII, and X, prothrombin gene 20210G→A transition, and factor V Leiden in coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19: 1020-5.
11 Cortellaro M, Broschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, della Volpe A, Polli E. The PLAT study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb 1992; 12: 1063-70.
12 Salomaa V, Rasi V, Peekanen J, Vahtera E, Jauhiainen M, Vartiainen E, Myllylä G, Ehnholm C. Haemostatic factors and prevalent coronary heart disease; the FINRISK haemostasis study. Eur Heart J 1994; 15: 1293-9.
13 Folsom A, Wu K, Rosamond W, Sharrett A, Chambless L. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
14 Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
15 Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 1539-44.
16 Carvalho de Sousa J, Azevedo J, Soria C, Barros F, Ribeiro C, Parreira F, Caen JP. Factor VII hyperactivity in acute myocardial thrombosis: a relation to the coagulation activation. Thromb Res 1988; 51: 165-73.
17 Merlini PA, Ardissino D, Oltrona L, Broccolino M, Coppola R, Mannucci PM. Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 1995; 15: 1675-9.
18 Moor E, Silveira A, van’t Hooft F, Sountaka AM, Eriksson P, Blombäck M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
19 Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary artery disease. Thromb Haemost 1996; 75: 767-71.
20 Kario K, Miyata T, Sakata T, Matsuo T, Kato H. Fluorogenic assay of activated factor VII. Plasma factor VII levels in relation to arterial cardiovascular disease in Japanese. Arterioscler Thromb 1994; 14: 265-74.
21 Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J, Wu KK, Morrissey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost 1994; 71: 38-48.
22 Folsom A, Wu K, Shahar E, Davis C. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993; 13: 1829-36.
23 Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Results of the ECAT angina pectoris study group. Thromb Haemost 1995; 73: 561-7.
24 Benamer H, de Prost D, Bridey F, Boccara A, Brochet E, Himbert D, Sustendal L, Steg P, Assayag P. Gender difference in factor VII and in activated factor VII levels in unstable angina. Thromb Haemost 1996; 75: 981.
25 Eriksson M, Egberg N, Wamala S, Orth-Gomér K, Mittleman M, SchenckGustafsson K. Relationship between plasma fibrinogen and coronary heart disease in women. Arterioscler Thromb Vasc Biol 1999; 19: 67-72.
26 Silveira A, Green F, Karpe F, Blombäck M, Humphries S, Hamsten A. Elevated levels of factor VII activity in the postprandial state: effect of the factor VII Arg-Gln polymorphism. Thromb Haemost 1994; 72: 734-9.
27 Junger I, Walldius G, Holme I, Steiner E. Apolipoprotein B and A-1 in relation to serum cholesterol and triglycerides in 43 000 Swedish males and females. Int J. Clin Lab Res 1992; 21: 247-55.
28 Meade TW, Cooper JA, Chakrabarti R, Miller GJ, Stirling Y, Howarth DJ. Fibrinolytic activity and clotting factors in ischemic heart disease in women. BMJ 1996; 312: 1581.
29 Feng D, Tofler GH, Larson MG, O’Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Johnstone MT, Muller JE, D’Agostino RB, Levy D, Lind-paintner K. Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease. Arterioscler Thromb Vasc Biol 2000; 20: 593-600.
30 Bladbjerg EM, Møller L, Jespersen J. Is factor VII protein concentration (FVII:Ag) a thrombotic risk indicator?. Thromb Haemost 1998; 79: 1064-5.
31 Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: 1. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using and menopause. Thromb Haemost 1985; 54: 475-9.
32 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
33 Mennen LI, Schouten EG, Grobbee DE, Kluft C. Coagulation factor VII, dietary fat and blood lipids: A review. Thromb Haemost 1996; 76: 492-9.
34 Scarabin PY, Vissac AM, Kirzin JM, Bourgeat P, Amiral J, Agher R, Guize L. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol 1996; 16: 1170-6.
35 Danielsen R, Önundarson P, Thors H, Vidarsson B, Morrissey J. Activated and total coagulation factor VII, and fibrinogen in coronary artery disease. Scand Cardiovasc J 1998; 32: 87-95.
36 Silveira A, Karpe F, Johnsson H, Bauer K, Hamsten A. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Vasc Biol 1996; 16: 1333-39.
37 The Medical Research Council’s General Practice Research Framework.. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-41.
38 Nguyen ND, Ghaddar H, Stinson V, Chambless LE, Wu KK. ARIC Hemostasis Study - IV. Intraindividual variability and reliability of hemostatic factors. Thromb Haemost 1995; 73: 256-60.
39 Hamsten A, Eriksson P, Karpe F, Silveira A. Relationship of thrombosis and fibrinolysis to atherosclerosis. Current Opinion in Lipidology 1994; 5: 382-9.
40 van’t Hooft FM, Silveira A, Tornvall P, Iliadou A, Ehrenborg E, Eriksson P, Hamsten A. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood 1999; 93: 3432-41.